Vyvanse and MAOIs: Absolute Contraindication
Vyvanse (lisdexamfetamine) is absolutely contraindicated with MAOIs and must not be used concurrently or within 14 days of discontinuing an MAOI due to the risk of hypertensive crisis. 1
The Critical Safety Issue
The FDA drug label for Vyvanse explicitly states this as a contraindication, not merely a warning 1. When amphetamines like Vyvanse are combined with MAOIs, patients are at high risk of developing hypertensive crises—a potentially fatal medical emergency 2, 1. This occurs because:
- MAOIs block the breakdown of norepinephrine and other catecholamines
- Amphetamines cause massive release of these same neurotransmitters
- The combination creates dangerous accumulation leading to severe blood pressure elevations
A 2024 case report documented a hypertensive emergency with myocardial infarction (ST-elevation) in a patient combining an amphetamine with the MAOI tranylcypromine 3. This underscores that this is not a theoretical risk—it causes real morbidity and mortality.
Safe Transition Protocol
If switching from an MAOI to Vyvanse:
- Discontinue the MAOI completely
- Wait a minimum of 14 days before starting Vyvanse 1
- This washout period allows MAO enzyme regeneration
If switching from Vyvanse to an MAOI:
- Discontinue Vyvanse
- Wait at least 14 days before initiating the MAOI
- Monitor blood pressure during the transition
Additional Serotonin Syndrome Risk
Beyond hypertensive crisis, the combination also risks serotonin syndrome—another potentially life-threatening condition 1. Symptoms include mental status changes, autonomic instability (tachycardia, labile blood pressure, hyperthermia), neuromuscular symptoms (rigidity, myoclonus), and seizures.
The Exception That Proves the Rule
While older literature 4, 5 describes rare cases where experienced clinicians have cautiously combined stimulants with MAOIs in treatment-refractory situations, these represent exceptional circumstances requiring:
- Failure of all other treatment options
- Extremely close monitoring of vital signs
- Specialized expertise in psychopharmacology
One 2015 case report documented successful use of transdermal selegiline with lisdexamfetamine 4, but emphasized this "should be used cautiously and with ongoing monitoring." However, this does not change the FDA contraindication and should not be attempted in routine clinical practice.
Clinical Bottom Line
Do not prescribe Vyvanse to any patient currently taking an MAOI or who has taken an MAOI within the past 14 days. The risk of hypertensive crisis and death outweighs any potential benefit. If a patient requires both ADHD treatment and an antidepressant, consider non-stimulant ADHD medications (atomoxetine, guanfacine, clonidine) 6 or switch the MAOI to a different antidepressant class that doesn't interact with stimulants.
The guideline evidence confirms that stimulants do not interact dangerously with SSRIs or most other antidepressants 2, making these safer alternatives when treating comorbid ADHD and depression.